Effects of Exenatide on Measures of β-Cell Function After 3 Years in Metformin-Treated Patients With Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: We previously showed that exenatide (EXE) enhanced insulin secretion after 1 year of treatment, relative to insulin glargine (GLAR), with a similar glucose-lowering action. These effects were not sustained after a 4-week off-drug period. This article reports the results after additional 2 years of exposure. RESEARCH DESIGN AND METHODS: Sixty-nine metformin-treated patients with type 2 diabetes were randomized to EXE or GLAR. Forty-six patients entered the 2-year extension study in which they continued their allocated therapy. Thirty-six completed (EXE: n = 16; GLAR: n = 20) the 3-year exposure period. Insulin sensitivity (M value) and β-cell function were measured by euglycemic hyperinsulinemic clamp followed by hyperglycemic clamp with arginine stimulation at pretreatment (week 52) and 4 weeks after discontinuation of study medication (week 56 and week 172). First-phase glucose stimulated C-peptide secretion was adjusted for M value and calculated as the disposition index (DI). RESULTS: At 3 years, EXE and GLAR resulted in similar levels of glycemic control: 6.6 ± 0.2% and 6.9 ± 0.2%, respectively (P = 0.186). EXE compared with GLAR significantly reduced body weight (−7.9 ± 1.8 kg; P < 0.001). After the 4-week off-drug period, EXE increased the M value by 39% (P = 0.006) while GLAR had no effect (P = 0.647). Following the 4-week off-drug period, the DI, compared with pretreatment, increased with EXE, but decreased with GLAR (1.43 ± 0.78 and −0.99 ± 0.65, respectively; P = 0.028). CONCLUSIONS: EXE and GLAR sustained HbA1c over the 3-year treatment period, while EXE reduced body weight and GLAR increased body weight. Following the 3-year treatment with EXE, the DI was sustained after a 4-week off-drug period. These findings suggest a beneficial effect on β-cell health.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“none of these agents have produced a meaningful, persistent change following therapy withdrawal ( 71 , 73 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [73]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The long-term effects of GLP-1RA go beyond the improvement in glucose metabolism and weight loss [34,35,36,37,38,39] and it is now established their beneficial effects of hepatic metabolism and histology.”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [35]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Further analyses from TODAY show that in youth with type 2 diabetes dyslipidaemia162 and hypertension163 are common and worsen over time.”
From Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future (2014) · cites this paper as [162]
Experimental — accuracy not yet measuredIn the citing paper
“In one study of exenatide,25 patients underwent two treatment phases—52 weeks followed by 104 weeks—with a 12-week off-treatment period after each phase.”
From Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression (2026) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 3×
“EXE predominantly lowers postprandial glucose by a glucose-dependent stimulation of insulin secretion, inhibition of an inappropriate glucagon secretion, and by slowing down gastric emptying (6).”
BackgroundResultInfluentialNathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 1×
“Although human data are not available, exposure to GLP-1 and GLP-1RA in the preclinical setting results in b-cell proliferation, islet neogenesis, and inhibition of b-cell apoptosis in (human) cell lines, primary rodent islets, and in vivo in different rodent species (13).”
BackgroundKahn, S. E. (2003) · Diabetologia · doi:10.1007/s00125-002-1009-0 · Cited by 2,166
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405 · cited 2×
“The disposition index (DI), a measure of b-cell function and adjusted for insulin sensitivity, was calculated bymultiplying the firstphase incremental C-peptide secretion with the M value (AIRgluc*M) (12).”
BackgroundMethodZander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“(21) was the first to report a beneficial effect of continuous GLP-1 infusion on clamp-measured b-cell function as well as insulin sensitivity in the presence of concomitant weight loss of 1.”
BackgroundCauter, E. V., Mestrez, F., Sturis, J., & Polonsky, K. S. (1992) · Diabetes · doi:10.2337/diab.41.3.368 · Cited by 890
DeFronzo, R. A. (2010) · Diabetologia · doi:10.1007/s00125-010-1684-1 · Cited by 879
Cited by
Items 201–241 of 241
Abdelgani, S., PUCKETT, C. L., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14383 · Cited by 6
Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function
Welters, A., & Lammert, E. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_474 · Cited by 5
Rasalam, R. R., Abdo, S., Deed, G., O’Brien, R. C., & Overland, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14953 · Cited by 7
Heart Failure in Diabetes Mellitus: An Updated Review
Sohrabi, C., Saberwal, B., Lim, W. Y., Tousoulis, D., Ahsan, S., & Παπαγεωργίου, Ν. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118091659 · Cited by 5
RECENT ADVANCES IN TREATMENT APPROACHES FOR DIABETES MELLITUS AND RELATED COMPLICATIONS: A REVIEW
Dhyani, S., Butola, M., Sautha, V., & Jakhmola, V. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i2.53184 · Cited by 11
Personalized approach for type 2 diabetes pharmacotherapy: where are we and where do we need to be?
Abdul‐Ghani, M. A., & DeFronzo, R. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1967319 · Cited by 5
“GLP-1 RAs exert a powerful effect on the beta cell to augment insulin secretion, resulting in a potent and durable reudction in plasma glucose concentration and HbA1c [73,74].”
BackgroundSu, Y., Zhang, S., Wu, Z., Liu, W.-T., Chen, J., Deng, F., Chen, F., Zhu, D., & Hou, K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1054946 · Cited by 5
“In our study, both short-acting and long-acting GLP-1 receptor agonists can reduce the levels of FPG, 2hPG, and HbAlc, which is consistent with previous studies (31).”
ResultGrandy, S., & Shaunik, A. (2015) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.1000643 · Cited by 6
“Thirty-six patients completed the 2-year extension study [26].”
BackgroundRajput, R., Sinha, B., Lodha, S., Deb, P., Das, S., Agarwal, S., Das, A. K., & Thomas, N. (2022) · Clinical Diabetology · doi:10.5603/dk.a2022.0026 · Cited by 6
“GLP-1 RAs improve b-cell glucose sensitivity, and effects can be observed within 8 h postinjection of GLP-1 ra (liraglutide) [23]; this effect can be maintained for 3 months (semaglutide) [24], and can persist for 3 years (exenatide) [25].”
BackgroundBarakat, G. M., Assi, G., Khalil, H., & Khatib, S. E. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998287178240403055901 · Cited by 3
Bashier, A. M., Abdelgadir, E., Khalifa, A. A., Rashid, F., Abuelkeir, S. M., & Bachet, F. (2014) · Saudi Medical Journal · doi:10.15537/1658-3175.6088 · Cited by 2
Islam, M., & Kabir, Y. (2022) · Frontiers in cardiovascular drug discovery · doi:10.2174/9789815036909122060007 · Cited by 2
Bokvist, K. B., Ding, Y., Landschulz, W. H., Sinha, V. P., Pastrak, A., & Belin, R. M. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13695 · Cited by 2
“In conclusion, based on promising preclinical data and our previous findings with [1-51] EGF plus TT223, we studied a combination of GLP-1RA and gastrin analogue for lasting, post-treatment glycaemic improvements in patients with T2DM.”
MethodThe world congress on insulin resistance, diabetes, and cardiovascular disease ( WCIRDC )
Bloomgarden, Z. T. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13260 · Cited by 2
Coghlan, M. P., & Fairman, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397176-0.00006-6 · Cited by 2
Combination therapy in type 2 diabetes mellitus
Abdul‐Ghani, M. A., DeFronzo, R. A., & Eldor, R. (2015) · Wiley eBooks · doi:10.1002/9781118387658.ch46 · Cited by 3
Beta-cell preservation in T2DM using a pathophysiologic approach
Papatheodorou, K., & Shubrook, J. H. (2025) · Postgraduate Medicine · doi:10.1080/00325481.2025.2494502 · Cited by 3
“This suggests that a longer period of treat-ment with exenatide may be needed to have prolonged benefits on beta-cell function [27].”
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Liu, Y., Gang, X., Liu, X., Jiang, W., Yang, Y., & Wang, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1687601 · Cited by 3
Incretin based therapies: Do they hold their promise?
Holst, J. J. (2012) · Journal of Diabetes · doi:10.1111/j.1753-0407.2012.00186.x · Cited by 1
Extra Glycemic Impacts of GLP-1 Receptor Agonists: Benefits of a Class Effect?
Araújo, L. M. D. M., Feguri, S., de Oliveira, T. L., Pedrosa, F. B., Guimarães, R. G., de Sá, L. B. P. C., Rocha, D. R. T. W., & Arbex, A. K. (2016) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2016.61007 · Cited by 2
“In animal studies in preclinical stage, there was an increase in C cell hyperplasia frequency and thyroid cancer among mice and rats exposed to liraglutide [48].”
BackgroundEvaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation
Paldánius, P. M. (2020) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0179 · Cited by 2
“Long-term administration of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) compared with insulin glargine or placebo after 4 weeks of intensive insulin therapy resulted in improved or superior β-cell function; this effect was either partially maintained [26,27], or lost after cessation of the incretin therapy […”
BackgroundManchi, R. K., Chenchula, S., & Haritha, M. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998292943240730115310 · Cited by 2
Effects of treatment of NAFLD on the metabolic syndrome
Yki‐Järvinen, H. (2016) · Wiley eBooks · doi:10.1002/9781118924938.ch21 · Cited by 1
Self-citationGameel, A., Altonbary, A. Y., Kyrillos, F. A., & Elbialy, A. (2023) · Research Square · doi:10.21203/rs.3.rs-3196471/v1 · Cited by 1
Budini, B., Luo, S., Tam, M., Stead, I., Lee, A. S., Akrami, A., Vidal‐Puig, A., & Park, A. (2025) · medRxiv · doi:10.1101/2025.06.09.25328726 · Cited by 1
Verbesserung der pankreatischen β-Zellfunktion bei Typ-2-Diabetes unter Therapie mit Liraglutid
KAHL, S. (2014) · Der Diabetologe · doi:10.1007/s11428-014-1307-4
ApproachtoTherap y in Patients With Newly Diagnosed Type 2 Diabetes
DeFronzo, R. A., & Eldor, R. (2013)
Combination therapy of GLP-1 analogues and insulin: do the benefits outweigh the costs?
Versmissen, J. (2014) · PubMed
Incretin – based therapy in diabetes mellitus: present scenario and expanding horizons
Kohli, S. C. (2016) · Nepal Journal of Epidemiology · doi:10.3126/nje.v6i2.15159
Adipositas und Prädiabetes: Therapie mit GLP‑1 Rezeptoragonisten
Ritzel, R. A. (2017) · Der Diabetologe · doi:10.1007/s11428-017-0274-y
Clinical and basic studies of GLP-1 receptor agonists for the treatment of diabetes in China
Hong, T., Liu, J., & Wei, R. (2018) · Scientia Sinica Vitae · doi:10.1360/n052018-00030 · Cited by 1
Glucotoxicité et lipotoxicité dans le diabète de type 2 : comment protéger la cellule β ?
Scheen, A. J. (2020) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2020.05.005 · Cited by 2
Preface: Cardiorenal Considerations for Type 2 Diabetes—Time to Exit the Dark Ages
DeFronzo, R. A., & Editor, G. (2021) · Diabetes Spectrum · doi:10.2337/ds20-0081
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-45015-5_20 · Cited by 1
Utzschneider, K. M., Ehrmann, D. A., Arslanian, S. A., Barengolts, E., Buchanan, T. A., Caprio, S., Edelstein, S. L., Hannon, T. S., Kahn, S. E., Kozedub, A., et al. (2022) · Obesity · doi:10.1002/oby.23475
“However, in an extension study in which 21 of the original 36 participants randomized to exenatide continued on treatment for another 2 years, β-cell function was increased despite 4 weeks of treatment withdrawal, suggesting a more sustained impact on β-cell health with longer-term exposure [27].”
ResultGameel, A., Altonbary, A. Y., Kyrillos, F. A., & Elbialy, A. (2025) · The Egyptian Journal of Internal Medicine · doi:10.1186/s43162-025-00443-8 · Cited by 2
“But unfortunately, when the drug stopped, weight gain may occur [21] .”
Gfi1 : a new target for diabetes therapy
Napolitano, T. (2017) · theses.fr (ABES) · doi:10.70675/aaf52a4az6ce1z446czae57z0d918d5706d5
Introduction to Pediatric Diabetes Mellitus
Rajan, R., Kapoor, N., & Kalra, S. (2026) · Contemporary Endocrinology · doi:10.1007/978-3-032-17036-1_1
Gli standard di cura terzo step: incretina + metformina
Giandalia, A., Romeo, E. L., Zingale, R., Alecci, U., & Russo, G. T. (2014) · MEDIA - Aggiornamento e formazione in diabetologia e malattie metaboliche
Metadata
- Authors
- Bunck, M. C., Cornér, A., Eliasson, B., Heine, R. J., Shaginian, R. M., Taskinen, M.-R., Smith, U., Yki-Järvinen, H., & Diamant, M.
- Affiliations
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Helsinki University Hospital (FI)
- Lundberg Laboratory for Diabetes Research, Sahlgrenska University Hospital, Goteborg, Sweden
- Eli Lilly (United States) (US)
- Eli Lilly (Netherlands) (NL)
- Sahlgrenska University Hospital (SE)
- Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
- Diabetes Center, Department of Internal Medicine, VU University Medical Center, Amsterdam, the Netherlands
- Corresponding author
- Bunck, Mathijs C.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2011-08-19
- Volume
- 34
- Issue
- 9
- Pages
- 2041-2047
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3161303
- OpenAlex
- W2029228033
- Cited by
- 240
- References
- 25
- Citations by year
- 2026: 2 · 2025: 7 · 2024: 5 · 2023: 10 · 2022: 11 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 20 · 2017: 29 · 2016: 24 · 2015: 23 · 2014: 27 · 2013: 28 · 2012: 12
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- exenatide, insulin glargine, type 2 diabetes, metformin, beta-cell function, insulin secretion, insulin sensitivity, disposition index, glycemic control, body weight, long-term treatment, GLP-1 receptor agonists
- MeSH terms
- Insulin Glargine, Exenatide, Adult, Aged, Blood Glucose, Body Weight, C-Peptide, Diabetes Mellitus, Type 2, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Venoms, Insulin, Long-Acting, Insulin-Secreting Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.